Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Non-small cell lung cancer is one of the most common types of malignances worldwide and the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical resection, chemotherapy, radiotherapy, and targeted therapy, with poor therapeutic effectiveness. In recent years, immune...

Full description

Bibliographic Details
Main Authors: Shengjie Tang, Chao Qin, Haiyang Hu, Tao Liu, Yiwei He, Haiyang Guo, Hang Yan, Jun Zhang, Shoujun Tang, Haining Zhou
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cells
Subjects:
non-small cell lung cancer
immune checkpoint inhibitors
PD-1/PD-L1
CTLA-4
immunotherapy
biomarkers
Online Access:https://www.mdpi.com/2073-4409/11/3/320

Internet

https://www.mdpi.com/2073-4409/11/3/320

Similar Items